FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:622 February 5, 2004 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hays, J. PubMed Citation

To the Editor: Hays et al. (May 8 issue)¹ conclude that among postmenopausal women enrolled in the Women's Health Initiative (WHI) trial, use of an estrogen–progestin combination did not have a clinically meaningful effect on health-related quality of life, except for a benefit with regard to sleep disturbances among women 50 to 54 years old who had moderate-to-severe vasomotor symptoms. However, the estrogen–progestin combination was associated with significant improvements in the severity of hot flashes and night sweats among women with moderate-to-severe vasomotor symptoms. These findings are clinically relevant and may be used by physicians and menopausal women to guide . . . [Full Text of this Article]

This article has been cited by other articles:

• Welton, A. J, Vickers, M. R, Kim, J., Ford, D., Lawton, B. A, MacLennan, A. H, Meredith, S. K, Martin, J., Meade, T. W, for the WISDOM team, (2008). Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 337: a1190-a1190 [Abstract] [Full Text]